Home PipelineEnoblituzumab (anti-B7-H3)


Enoblituzumab is an investigational monoclonal antibody that targets B7-H3 and has been enhanced using MacroGenics’ Fc Optimization platform. B7-H3 is a protein in the B7 family of immune regulator proteins. B7-H3 is widely expressed by a number of different tumor types and may play a key role in regulating the immune response to various types of cancer.

Clinical Development

Please refer to our most recent corporate deck on our Events & Presentations page for the latest clinical information available on enoblituzumab.

Our Rights

MacroGenics retains global rights to enoblituzumab.

Clinical Trials

Presentations & Publications

Relevant Publications and Presentations can be found at https://macrogenics.com/publications/.

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close